tbuckley/cabot-search huggingface dataset:
Spontaneous rupture and ulceration of atherosclerotic plaques: In vivo assessment of the size of 51 emptied plaque cavities and their relation with lesion characteristics Clemens von Birgelen, Wolfgang Klinkhart, Gary S. Mintz, Christoph Kaiser, J�rg Herrmann, Dietrich Baumgart, Michael Haude, Heinrich Wieneke, Thomas Bartel, Dirk B�se, Helge Bast, Raimund Erbel. University Essen, Cardiology Department, Essen, Germany, Washington Hospital Center, Washington D.C.
Journal: Journal of the American College of Cardiology (2001)
Age-dependent impairment of reendothelialization after arterial injury: role of VEGF Fran�ois Gauthier, Giuseppa Gennaro, Catherine M�nard, Sophie Elise Michaud, Alain Rivard. Centre Hospitalier de l'Universit� de Montr�al, Montr�al, PQ, Canada
Journal: Journal of the American College of Cardiology (2001)
Downregulation of low-density lipoprotein receptor mRNA in lymphatic endothelial cells impairs lymphatic function through changes in intracellular lipids
Authors: Laurent Vachon, Ali Smaani, Nolwenn Tessier, Gabriel Jean, Annie Demers, Andreea Milasan, Nadine Ardo, Stéphanie Jarry, Louis Villeneuve, Azadeh Alikashani, Vincent Finherty, Matthieu Ruiz, Mary G. Sorci-Thomas, Gaétan Mayer, Catherine Martel
Journal: Theranostics (2022)

Impairment in lymphatic transport is associated with the onset and progression of atherosclerosis in animal models. The downregulation of low-density-lipoprotein receptor (LDLR) expression, rather than increased circulating cholesterol level
Extension of Endocardium-Derived Vessels Generate Coronary Arteries in Neonates
Authors: Juan Tang, Huan Zhu, Xueying Tian, Haixiao Wang, Shaoyan Liu, Kuo Liu, Huan Zhao, Lingjuan He, Xiuzhen Huang, Zhao Feng, Zhangheng Ding, Ben Long, Yan Yan, Nicola Smart, Hui Gong, Qingming Luo, Bin Zhou
Journal: Circulation Research (2022)

Unraveling how new coronary arteries develop may provide critical information for establishing novel therapeutic approaches to treating ischemic cardiac diseases. There are 2 distinct coronary vascular populations derived from different origins in the developing heart. Understanding the formation of coronary arteries may provide insights into new ways of promoting coronary artery formation after myocardial infarction.To understand how intramyocardial coronary arteries are generated to connect these 2 coronary vascular populations, we combined genetic lineage tracing, light sheet microscopy, fluorescence micro-optical sectioning tomography, and tissue-specific gene knockout approaches to understand their cellular and molecular mechanisms.We show that a subset of intramyocardial coronary arteries form by angiogenic extension of endocardium-derived vascular tunnels in the neonatal heart. Three-dimensional whole-mount fluorescence imaging showed that these endocardium-derived vascular tunnels or tubes adopt an arterial fate in neonates. Mechanistically, we implicate Mettl3 (methyltransferase-like protein 3) and Notch signaling in regulating endocardium-derived intramyocardial coronary artery formation. Functionally, these intramyocardial arteries persist into adulthood and play a protective role after myocardial infarction.A subset of intramyocardial coronary arteries form by extension of endocardium-derived vascular tunnels in the neonatal heart.
Effect of a cancer tracking system on timeliness of liver cancer care at a Veteran's Hospital.
Authors: Amanda Ivatorov, Catherine Mezzacappa, Tamar Hamosh Taddei
Journal: Journal of Clinical Oncology (2022)

406 Background: Hepatocellular carcinoma (HCC) requires complex care coordination with opportunities for care delays and untimely follow-up of abnormal liver imaging results. An electronic medical record-linked abnormal imaging identification and tracking system was implemented at a Veterans Affairs Hospital. The system reviews all liver radiology reports, generates a queue of abnormal cases for care coordinator review, and provides a tracking feature to monitor each patient’s care. Methods: This is a pre-/post-intervention study to evaluate whether implementation of this tracking system reduced (1) time between HCC diagnosis and treatment and (2) time from first suspicious image to first specialty care appointment, diagnosis, and treatment. Patients diagnosed with HCC in the 37-months before tracking system implementation (pre-intervention) were compared with patients diagnosed with HCC in the 71-months (less an 11-month grace period) after tracking system implementation (post-intervention). Linear regression was used to calculate mean change in relevant intervals of care pre- and post-intervention adjusted for patient age, race, ethnicity, BCLC stage at diagnosis, and indication for first suspicious image. Results: There were 60 patients in the pre-intervention period and 127 in the post-intervention period. The post-intervention group had a greater proportion of HCC diagnosed at earlier BCLC stages (p&lt;0.03). Compared to the pre-intervention cohort, the post-intervention cohort had an adjusted mean reduction of 36 days from diagnosis to treatment (p=0.007), 51 days from suspicious imaging to diagnosis (p=0.21), and 87 days from suspicious imaging to treatment (p=0.05). Stratified by indication for first suspicious imaging, patients whose imaging was performed for HCC screening had the greatest decreases in time from diagnosis to treatment (63 days, p=0.02) and from first suspicious image to treatment (179 days, p=0.03). Conclusions: Our tracking system improved timeliness of HCC diagnosis and treatment. We anticipate it may improve HCC care coordination and delivery, including when added to HCC screening protocols.[Table: see text]
Survival outcomes associated with chemotherapy-induced neutropenia in the adjuvant treatment of colorectal cancer with FOLFOX.
Authors: Sara Trincao-Batra, Rachel Anne Goodwin, Horia Marginean, Jean Alfred Maroun, Michael M. Vickers, Timothy R. Asmis, Joanna Gotfrit
Journal: Journal of Clinical Oncology (2022)

81 Background: Patients undergoing adjuvant treatment with FOLFOX for colorectal cancer (CRC) are at risk of developing chemotherapy-induced neutropenia (CIN). We assessed survival outcomes in patients who develop CIN in this setting. Methods: We performed a retrospective chart review of patients with CRC treated with FOLFOX at our institution in Canada from 2013 to 2015. The survival follow-up cut-off date was August 2021. Demographic, treatment, and outcome data were collected. CIN was defined as ANC &lt;1.5, and all episodes of neutropenia were assumed to be the result of chemotherapy. Median OS was calculated using Kaplan-Meier product limit estimates. Results: A total of 302 patients were included (baseline demographics in the table). Median follow-up was 110 months. In the overall cohort, 174 patients (58%) had at least one episode of CIN. CIN occurred in 56% of those with stage II cancer, 43% of those with low risk stage III cancer (T1-3 and N1), and 45% of those with high risk stage III cancer (T4 or N2). Median time to first CIN event was 4.3 months. Among patients with at least one episode of CIN, the first CIN event occurred during the first 3 months of treatment in 110 (63%). Among patients with at least one episode of CIN, 79 (45%) received subsequent granulocyte colony-stimulating factor (GCSF). The median OS in the overall cohort was 171 months. For patients with and without CIN the median OS had not been reached, HR 0.84 (95% CI 0.55-1.29, p=0.43). The median OS for patients with CIN treated with and without GCSF had not been reached, HR 1.02 (95% CI 0.57-1.82, p=0.94). The 5-year survival rate for patients with and without CIN was 87% vs 77%. The 10-year survival rate for patients with and without CIN was 70% vs 64%. A trend toward improved survival in those with CIN remained when results were analyzed by cancer stage. Conclusions: Patients with CIN had a trend toward improved survival compared to those who did not have CIN. There was no indication that GCSF in the setting of CIN impacted survival. The causes for the potentially protective effect of CIN in the setting of adjuvant CRC treatment require further elucidation.[Table: see text]
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
Authors: Craig T. January, L. Samuel Wann, Joseph S. Alpert, Hugh Calkins, Joaquin E. Cigarroa, Joseph C. Cleveland, Jamie B. Conti, Patrick T. Ellinor, Michael D. Ezekowitz, Michael E. Field, Katherine T. Murray, Ralph L. Sacco, William G. Stevenson, Patrick J. Tchou, Cynthia M. Tracy, Clyde W. Yancy
Journal: Journal of the American College of Cardiology (2014)
Ninth Annual Congress of the Oncology Nursing Society
Journal: JNCI Journal of the National Cancer Institute (1984)

Ninth Annual Congress of the Oncology Nursing Society JNCI: Journal of the National Cancer Institute, Volume 72, Issue 1, January 1984, Page 199, https://doi.org/10.1093/jnci/72.1.199-a Published: 01 January 1984
Corrigendum to “Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria”
Authors: J.J. Gao, D. Krol, P. Narayan, F. Cardoso, M.M. Regan, M.P. Goetz, S.A. Hurvitz, L. Mauro, C. Hodgdon, C.P. Miller, B. Booth, E. Bloomquist, G. Ison, C. Osgood, V. Bhatnagar, L. Fashoyin-Aje, R. Pazdur, L. Amiri-Kordestani, J.A. Beaver
Journal: Annals of Oncology (2022)
Fewer bleeding complications with comparable efficacy with the transradial approach in coronary artery stenting: An analysis of the ESPRIT trial John Conor O'Shea, Tift Mann, Anne Hellkamp, Eric Cohen, Robert Chrisholm, Warren J. Cantor, Ian Gilchrist, William Meengs, Michael M. Kitt, Todd J. Lorenz, James E. Tcheng. Duke Clinical Research Institute, Durham, NC
Journal: Journal of the American College of Cardiology (2001)
Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome
Authors: Marcella Kaddoura, Moritz Binder, David Dingli, Francis K. Buadi, Martha Q. Lacy, Morie A. Gertz, Angela Dispenzieri, Prashant Kapoor, Lisa Hwa, Amie Fonder, Miriam Hobbs, Suzanne Hayman, Nelson Leung, Ronald S. Go, Yi Lin, Wilson Gonsalves, Taxiarchis Kourelis, Rahma Warsame, Robert A. Kyle, Vincent Rajkumar, Shaji Kumar
Journal: American Journal of Hematology (2022)

Achievement of a complete response (CR) in multiple myeloma (MM) correlates with improvement in survival outcomes; however, its impact on prognostic variables at baseline outside of clinical trial settings is not well described. We sought to determine the impact of achieving a CR within 2 years from diagnosis, its effect on the prognostic value of fluorescence in situ hybridization (FISH) and International Staging System (ISS) risk, and examined additional predictors of outcome among those achieving a CR in a routine clinical setting. We evaluated 1869 newly diagnosed MM patients who had ≥ 2 monoclonal protein immunofixation studies in the serum and urine available within 24 months from diagnosis, categorizing those with ≥ 2 negative serum and urine immunofixations as achieving CR. With a landmark at 24 months, median progression-free survival (PFS) for CR versus non-CR patients was 29.8 versus 20.9 months (p ≤ .0002); median overall survival (OS) was 104 versus 70 months (p < .0001). The impact of achieving a CR was retained after adjusting for FISH, ISS, sex, transplant status, and involved heavy chain. Baseline FISH and ISS stage were not associated with PFS or OS among patients achieving a CR. The following variables were found as predictors of inferior OS within the CR cohort: age > 75 years, male gender, hypoalbuminemia, and non-immunoglobulin G involved heavy chain. Our study confirms that achievement of CR within 2 years from diagnosis is associated with improvement in survival outcomes and neutralization of the impact of FISH and ISS risk, thereby confirming observations from the clinical trial setting among a clinical practice cohort.
Immunotherapy Withdrawals Put Spotlight on Accelerated Approval
Journal: Cancer Discovery (2021)

The FDA's Accelerated Approval program is under scrutiny after four drug companies announced plans in recent months to withdraw indications for checkpoint inhibitors that, despite showing early promise, failed to demonstrate a survival benefit in confirmatory trials. The agency's Oncologic Drugs Advisory Committee will meet in late April to discuss whether six more indications for some of these same immunotherapies should be nullified as well.
First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A
Authors: J.M.G. Larkin, S.S. Tykodi, F. Donskov, J.-L. Lee, C. Szczylik, J. Malik, B.Y. Alekseev, V.B. Matveev, R.A. Gafanov, P. Tomczak, P.F. Geertsen, P.J. Wiechno, S.J. Shin, F. Pouliot, T. Alonso Gordoa, R. Kloss Silverman, R.F. Perini, C. Schloss, D.F. McDermott, M.B. Atkins
Journal: Annals of Oncology (2019)
Neurologic Manifestations of HIV Infection
Authors: David M. Simpson
Journal: Annals of Internal Medicine (1995)

Letters1 June 1995Neurologic Manifestations of HIV InfectionDavid M. Simpson and Michele TaglianiDavid M. SimpsonSearch for more papers by this author and Michele TaglianiSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-122-11-199506010-00029 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We thank the correspondents for their comments. Dr. Harindra correctly notes that cerebrovascular disease should be included in the differential diagnosis of focal neurologic lesions in HIV-infected patients, particularly when the deficits are transient or apoplectic in onset. We and others [1, 2] have reported several mechanisms of cerebrovascular disease in these patients, including nonbacterial thrombotic endocarditis and hemorrhage associated with thrombocytopenia. Vasculitis may be associated with syphilis, herpes zoster, and other viral infections, but the frequency of these disorders in HIV infection is unclear. Although the role of HIV infection in cerebrovascular disease is unknown, Brew and ...References1. Snider WD, Simpson DM, Nielsen S, Gold JW, Metroka CE, Posner JB. Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. Ann Neurol. 1983; 14:403-18. Google Scholar2. Silvestrini M, Floris R, Tagliati M, Stanzione P, Sancesario G. Spontaneous subarachnoid hemorrhage in an HIV patient. Ital J Neurol Sci. 1990; 11:489-92. Google Scholar3. Brew BJ, Miller J. Transient ischemic attacks in HIV-1 infection. Clin Neuropathol. 1993; 12(Suppl 1):S15. Google Scholar4. Musher DM, Baughn RE. Neurosyphilis in HIV-infected patients (Editorial). N Engl J Med. 1994; 331:1516-7. Google Scholar5. Davis LE, Schmitt JW. Clinical significance of cerebrospinal fluid tests for neurosyphilis. Ann Neurol. 1989; 25:50-5. Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 June 1995Volume 122, Issue 11Page: 883-884KeywordsCerebrospinal fluidCerebrovascular diseasesHIV infectionsLesionsNeuropathyPolymyositisSpecificitySyphilisTransient ischemic attacksVasculitis ePublished: 15 August 2000 Issue Published: 1 June 1995 Copyright & PermissionsCopyright © 1995 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Comments on Intraoperative Molecular Imaging for Localizing Nonpalpable Tumors
Authors: Dong Lin, Liang Wu, Jiang Fan
Journal: JAMA Surgery (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Viscerotropic Leishmaniasis in Persons Returning From Operation Desert Storm—1990-1991
Journal: JAMA (1992)

From November 1990 through December 1991, seven men among the approximately 500,000 military personnel from the United States who participated in Operation Desert Storm had leishmaniasis involving internal organs diagnosed at Walter Reed Army Medical Center. In at least five of the cases, the species of the infecting parasite was Leishmania tropica (previously known as L. tropica minor), a parasite more commonly associated with cutaneous than with visceral leishmaniasis.
From the Editor's Desk…
Authors: Patrizia Burra, Frank Tacke, Vlad Ratziu, Stefan Zeuzem, Bruno Sangro, Paolo Angeli
Journal: Journal of Hepatology (2020)

In this issue, Cai Q. et al. evaluated the clinical characteristics of patients with COVID-19 and abnormal liver tests. Clinical records and laboratory results were obtained from 417 patients with laboratory confirmed COVID-19 who were admitted to the only referral hospital in Shenzhen, China. Of 417 patients with COVID-19, 318 (76.3%) had abnormal liver tests and 90 (21.5%) had liver injury during hospitalisation. The presence of abnormal liver tests became more pronounced during hospitalisation.
Total plaque burden in early atherosclerosis: Can it be predicted by the most severe lesion? Samir R. Kapadia, Khaled M. Ziada, Timothy D. Crowe, Debabrata Mukherjee, Robert E. Hobbs, Steven E. Nissen, E. Murat Tuzcu. The Cleveland Clinic Foundation, Cleveland, OH
Journal: Journal of the American College of Cardiology (2001)
Obituary Listing
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Nivolumab (NIVO) and drug eluting bead transarterial chemoembolization (deb-TACE): Updated results from an ongoing phase 1 study of patients (pts) with liver limited hepatocellular carcinoma (HCC).
Authors: James J. Harding, Hooman Yarmohammadi, Kim Anna Reiss, Joanne F. Chou, Marinela Capanu, Richard K. G. Do, Danny Khalil, Imane H. El Dika, Christine S. Ferrer, Olivia Heffernan, J Daniel Giardina, Taha Merghoub, William R. Jarnagin, Gregory Nadolski, Joseph Patrick Erinjeri, Michael C. Soulen, Benjamin R. Tan, Ghassan K. Abou-Alfa
Journal: Journal of Clinical Oncology (2022)

437 Background: TACE is a standard of care for liver limited HCC and impacts the immune microenvironment, potentially augmenting the effects of immune checkpoint inhibitors. Methods: This is a multicenter phase 1 study of NIVO and deb-TACE in unresectable HCC pts and Child Pugh A cirrhosis (NCT03143270). The primary objective is to assess safety. Secondary objectives include response rate by RECIST v1.1, progression-free and overall survival by Kaplan-Meier methodology, and blood/tumor immune correlates. A 3 + 3 design with expansion cohort sequentially evaluates 3 cohorts of differing schedules of NIVO relative to deb-TACE. Deb-TACE (75mg of doxorubicin) is administered on Day 0. NIVO is dosed at 240mg IV every 14 days for 1 year (Cohort 1: NIVO begins day +14 after deb-TACE; Cohort 2, interrupted NIVO dosing begins at Day -28 but is held on the Day 0 then restarted on Day +14; Cohort 3, continuous NIVO dosing begins on Day -28 without interruption). Results: As of September 2021, 19 pts were treated [median 67 years (range: 54-78), male (80%), ECOG PS 0 (47%), Child Pugh A (100%), 3 pts in each cohort 1 and 2, 13 pts in cohort 3]. No cases of treatment related liver failure or Grade 5 adverse events (AEs) were observed. 1 DLT of Grade 3 transaminitis was observed in cohort 3 and resolved without intervention and did not recur with drug rechallenge. Median ALT at baseline, day 28, day 56, and end of treatment (EOT) were 27, 43.5, 36.5, and 29 U/L. Median bilirubin at baseline, day 28, day 56, and EOT were 0.6, 0.6, 0.5, and 0.6 mg/dL. Mean ALBI score at baseline (N=19) and EOT (N=14) were -2.75 ± 0.48 vs. -2.55 ± 0.50. The most common treatment-related AEs of any grade were fatigue (53%), ALT/AST increase (42%), fever (37%), and pruritis (32%). The objective response rate by RECIST v 1.1 was 21% (Table). 5/19 pts remained on study with SD or better for ≥12 (range 12-43) months. Updated survival analysis will be presented at the meeting; correlatives at a separate venue. Conclusions: Nivolumab administered with deb-TACE is safe with antitumor activity. This study provides a needed benchmark for the safety of embolization along with anti-PD1 therapy in liver limited HCC. The clinical question of combining immunotherapy with embolization to improve outcome over embolization alone remains investigational and several, pivotal, phase 3 studies are ongoing. Clinical trial information: NCT03143270. [Table: see text]